News from ISGlobal
Clínica Universidad de Navarra and the Barcelona Institute for Global Health (ISGlobal) have launched a clinical trial to investigate the efficacy of ivermectin against COVID-19. The aim of the study, carried out in collaboration with Idifarma, is to determine whether administration of ivermectin is associated with a shorter viral clearance time.
"Ivermectin has been shown to have an antiviral effect against other single-chain RNA viruses, including dengue and yellow fever, and it has successfully inhibited the replication of those viruses in vitro", explained Carlos Chaccour, a specialist affiliated with Clínica Universidad de Navarra and ISGlobal and principal investigator for the new study. "We are also interested in assessing the drug’s immunomodulatory role because one of the major problems with the SARS CoV-2 virus is the disordered immune response it causes".
Ivermectin was recently shown to inhibit the replication of SARS-CoV-2 in vitro at very high doses , but this effect has not yet been studied in vivo. The new study will investigate this question in a randomised trial. Twenty-four patients with mild disease and no risk factors will be given a single oral dose of ivermectin or placebo less than 48 hours after the onset of symptoms.